Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT05156749
Recruiting Not applicable

Short and Long-arm Fiberglass Cast Immobilization for Distal Salter Harris I and II Forearm Fractures in Children

NCT05156749 · tracked via the Priya Life Science Switzerland tracker
Sponsor
University Children's Hospital, Zurich
Phase
Not applicable
Started
2021-12-07
Last updated
2026-05-05

Condition(s) studied

Fracture Forearm

Investigational drug(s) / intervention(s)

short-arm fiberglass castlong-arm fiberglass cast

short-arm fiberglass cast: fracture stabilization of salter harris I/II fractures with a fiberglass short-arm cast

long-arm fiberglass cast: fracture stabilization of salter harris I/II fractures with a fiberglass long-arm cast

Study summary

The aim of this study is to investigate whether short-arm fiberglass cast (SAC) immobilization provides fracture stabilization comparable to that of long-arm cast (LAC) treatment of displaced and non-displaced distal Salter Harris I/II forearm fractures in paediatric patients.

Eligibility

Sex
ALL
Min age
4 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Salter Harris I or II fracture of the distal radius or a forearm fracture * informed consent Exclusion Criteria: * open/instable/intraarticular fracture * age \<4 years or \> 16years * no informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Children's Hospital Zurich Zurich Switzerland Recruiting

More University Children's Hospital, Zurich trials in Switzerland

Health Related Quality of Life (HrQoL) in Classical Homocystinuria (CBS Deficiency) Recruiting
Borrelia B-cell Diagnostics Recruiting
The Swiss Neurodevelopmental Outcome Registry for Children With CHD Recruiting
An Innovative Endoscopic Cap for Dilating Benign Esophageal Strictures in Children Recruiting
The Use of Cultured (Dermal) Epithelial Autografts in Severely Burned Patients Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05156749 on ClinicalTrials.gov ↗ ← All trials in Switzerland